Home > Products > Antibodies > Biosimilars

Research Grade Cendakimab (HW632016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HW632016
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
IsotypeIgG1-kappa
Expression systemMammalian Cells
SpeciesHuman
ClonalityMonoclonal
TargetIL13, NC30, Interleukin-13, IL-13
Endotoxin levelPlease contact with the lab for this information.
Purity>95% as determined by SDS-PAGE.
PurificationProtein A/G purified from cell culture supernatant.
AccessionP35225
FormLiquid
Storage buffer0.01M PBS, pH 7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate Names13C5.5, ABT-308, RPC-4046, CAS: 2151032-62-9
BackgroundCendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis).
NoteFor research use only. Not suitable for clinical or therapeutic use.
Images
  • Bioactivity

    Detects Human IL13 in indirect ELISAs.

References

Recommendation